ADVERTISEMENT

Review Pathway

EMA’s Combined Scientific Advice Seeks To Boost Approvals For Drugs Tackling Public Health Threats

A new service from the European Medicines Agency offers developers of products targeting public health emergencies combined regulatory advice on marketing authorization and clinical trials.

Korea’s New Health Minister: ‘Golden Time For The Country To Become A Biopharma Leader’

Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse.

Speedy FDA Review Could Save Stealth From Sinking

The agency is expected to give its final verdict on elamipretide by the end of September.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

Korea Pre-Review Consultations Help Accelerate R&D

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

How Will Regulatory Filing Winds Blow Globally For Elevidys Following Patient Deaths?

Roche’s filing for Elevidys in the EU followed applications in Middle Eastern countries because those markets accept applications based on approval by the US Food and Drugs Administration.

Lerodalcibep And First Generic Palbociclib Among 10 New EMA Filings

Lerodalcibep and palbociclib are among the latest new drugs that the European Medicines Agency has started to review for potential EU marketing authorization.

Alzheimer’s Drug Leqembi May Be On Course To India, Kisunla In The Wings

Key expert panel go-ahead with a trial waiver put’s Eisai's Alzheimer's therapy on track for a debut in India where tailored pricing will be pivotal. Lilly’s Kisunla is also under regulatory review.

PharmaMar Seeks EU Fast-Track Status For ‘Practice-Changing’ ES-SCLC Therapy

PharmaMar, which wants to use the Jazz Pharmaceuticals-partnered drug, lurbinectedin, in combination with Roche’s Tecentriq for treating extensive-stage small cell lung cancer, is one of two companies that this month sought an accelerated assessment of their planned EU marketing applications.

SpringWorks To Make Its Case For Nirogacestat At High-Stakes EMA Meeting

Nirogacestat was one of four products scheduled for an oral explanation meeting at the European Medicines Agency this week.

EMA To Consider Approvals For Eight Orphans, Including Vertex’s CF Drug Alyftrek

The European Medicines Agency is this week expected issue opinions on whether the European Commission should grant EU marketing authorization for 19 new products.

Sponsors Of Two Orphans And An Acne Treatment To Defend Marketing Authorization Applications At EMA

Sponsors of three drugs that are in the final stages of the EU regulatory review cycle are due to make the case for marketing approval before the European Medicines Agency.